Breaking News, Collaborations & Alliances

BioVectra, Keryx Enter Supply Agreement for Kidney Disease

The partnership revolves around the manufacture of Ferric Citrate, the API in Auryxia tablets

BioVectra Inc. has announced a long-term supply agreement with Keryx Biopharmaceuticals to manufacture Ferric Citrate, the active pharmaceutical ingredient (API) in Auryxia tablets, a medicine approved for the treatment of two common complications of chronic kidney disease.   BioVectra brings over 45 years of contract development and manufacturing experience to the partnership. They have previously worked with Keryx to manufacture Ferric Citrate API since 2003. BioVectra will prepare for...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters